Cytochrome P450

CYPs

Cytochrome p450 comprises a superfamily of heme-thiolate proteins named for the spectral absorbance peak of their carbon-monoxide-bound species at 450 nm. Having been found in every class of organism, including Archaea, the p450 superfamily is believed to have originated from an ancestral gene that existed over 3 billion years ago. Repeated gene duplications have subsequently given rise to one of the largest of multigene families. These enzymes are notable both for the diversity of reactions that they catalyze and the range of chemically dissimilar substrates upon which they act. Cytochrome p450s support the oxidative, peroxidative and reductive metabolism of such endogenous and xenobiotic substrates as environmental pollutants, agrochemicals, plant allelochemicals, steroids, prostaglandins and fatty acids. In humans, Cytochrome p450s are best known for their central role in phase I drug metabolism where they are of critical importance to two of the most significant problems in clinical pharmacology: drug interactions and interindividual variability in drug metabolism.

Cytochrome P450 Inhibitors, Activators, Modulators & Inducers

(+)-Ketoconazole

((+)-Ketoconazol; (+)-R 41400)

Cat. No.: HY-B0105A

(+)-Ketoconazole ((+)-R 41400) is an imidazole anti-fungal agent, a CYP3A4 inhibitor.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

(3S,5S)-Atorvastatin

Cat. No.: HY-B0589C

(3S,5S)-Atorvastatin is a inactive enantiomer of Atorvastatin. (3S,5S)-Atorvastatin can activate **pregnane X receptor (PXR)**. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(R)-Mephenytoin

((-)-Mephenytoin)

Cat. No.: HY-126043

(R)-Mephenytoin ((-)-Mephenytoin), the R-enantiomer of Mephenytoin. Mephenytoin is an Anticonvulsant agent.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

(Rac)-Brassinazole

Cat. No.: HY-121161

(Rac)-Brassinazole, triazole-type compound, is a **brassinosteroid (BR) biosynthesis** inhibitor. (Rac)-Brassinazole increases inhibition of **CYP90B** in BR biosynthesis.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

1-Aminobenzotriazole

(ABT; 3-Aminobenzotriazole)

Cat. No.: HY-103389

1-Aminobenzotriazole is a nonspecific and irreversible inhibitor of **cytochrome P450** (**P450**).



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

1-Ethynylnaphthalene

Cat. No.: HY-111430

1-Ethynylnaphthalene is a selective inhibitor of cytochrome **P450 1B1**.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 500 mg

1-Ethynylpyrene

Cat. No.: HY-131452

1-Ethynylpyrene is an aryl acetylenic inhibitor of **cytochromes P450 1A1**, **1A2**, and **2B1** with IC_{50}s of 0.18, 0.32, and 0.04 μM, respectively.



Purity: 96.20%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg

17-ODYA

Cat. No.: HY-101016

17-ODYA is a **CYP450 ω-hydroxylase** inhibitor.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

2,6-Dimethylquinoline

Cat. No.: HY-W010195

2,6-Dimethylquinoline, a nature constituent from the roots of Peucedantu praeruptorum, is a **CYP1A2** inhibitor with an IC_{50} of 3.3 μM. 2,6-Dimethylquinoline also inhibits **CYP2B6** activity with an IC_{50} of 480 μM.



Purity: 98.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

2-Phenyl-2-(1-piperidinyl)propane

Cat. No.: HY-W040468

2-Phenyl-2-(1-piperidinyl)propane is a selective and reversible human **CYP2B6** inhibitor with an IC_{50} of 5.1 μM and a K_i of 5.6. 2-Phenyl-2-(1-piperidinyl)propane inhibits CYP2D6 (IC_{50}=74 μM), CYP3A (IC_{50}=200 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

4'-Methylchrysoeriol

Cat. No.: HY-112734

4'-Methylchrysoeriol is a potent inhibitor of **Cytochrome P450** enzymes, with an IC_{50} of 19 nM for human P450 1B1-dependent EROD.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

4,5-Dimethoxycanthin-6-one

Cat. No.: HY-N1882

4,5-Dimethoxycanthin-6-one is a potent and uncompetitive inhibitor of **CYP1A2**-mediated phenacetin O-deethylation with an IC_{50} value of 1.7μM and a K_i value of 2.6 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

5,7-Dimethoxyflavone

Cat. No.: HY-N5011

5,7-Dimethoxyflavone is one of the major components of Kaempferia parviflora, has anti-obesity, anti-inflammatory, and antineoplastic effects. 5,7-Dimethoxyflavone inhibits cytochrome **P450 (CYP) 3As**.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg, 50 mg

7-Ethoxyresorufin

(Resorufin ethyl ether)

Cat. No.: HY-D0145

7-Ethoxyresorufin (Resorufin ethyl ether) is a fluorometric substrate and competitive inhibitor of **cytochrome P450**, especially **CYP1A1**. 7-Ethoxyresorufin also inhibits **NO synthase**.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

7-Ethoxyresorufin-d5

(Resorufin ethyl ether-d5)

Cat. No.: HY-D0145S

7-Ethoxyresorufin-d5 is deuterium labeled 7-Ethoxyresorufin. 7-Ethoxyresorufin (Resorufin ethyl ether) is a fluorometric substrate and competitive inhibitor of cytochrome P450, especially CYP1A1. 7-Ethoxyresorufin also inhibits NO synthase.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

8-Geranyloxypsoralen

Cat. No.: HY-N2262

8-Geranyloxypsoralen is a furanocoumarin isolated from grapefruit, acts as a potent inhibitor of **P450 3A4 (CYP3A4)** with an IC_{50} of 3.93 μM.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Abiraterone

(CB-7598)

Cat. No.: HY-70013

Abiraterone is a potent and irreversible **CYP17A1** inhibitor with antiandrogen activity, which inhibits both the 17α-hydroxylase and 17,20-lyase activity of the cytochrome p450 enzyme CYP17 with IC_{50}s of 2.5 nM and 15 nM, respectively.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Abiraterone acetate

(CB7630)

Cat. No.: HY-75054

Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of **CYP17A1** with antiandrogen activity. Abiraterone acetate is a prodrug form of Abiraterone (CB7598).



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Abiraterone acetate-d4

(CB7630-d4)

Cat. No.: HY-75054S

Abiraterone acetate-d4 (CB7630-d4) is the deuterium labeled Abiraterone acetate. Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of **CYP17A1** with antiandrogen activity. Abiraterone acetate is a prodrug form of Abiraterone (CB7598).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Abiraterone decanoate

Cat. No.: HY-145786

Abiraterone decanoate is a potent Abiraterone prodrug. Abiraterone decanoate provide a controlled release of Abiraterone and long-acting CYP17 inhibition with intramuscular (IM) delivery.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Abiraterone-D4

(CB-7598-D4)

Cat. No.: HY-70013S

Abiraterone-D4 (CB-7598-D4) is the deuterium labeled Abiraterone.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Acetylshikonin

Cat. No.: HY-N2181

Acetylshikonin, derived from the root of Lithospermum erythrorhizon, has anti-cancer and antiinflammation activity. Acetylshikonin is a non-selective **cytochrome P450** inhibitor against all P450s (IC_{50} values range from 1.4-4.0 μM).



Purity: 98.10%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

ACP-5862

Cat. No.: HY-135334

ACP-5862 is a major active, circulating, pyrrolidine ring-opened metabolite of Acalabrutinib with an IC_{50} of 5.0 nM for **Bruton tyrosine kinase (BTK)**. ACP5862 is a weak timedependent inactivator of **CYP3A4** and **CYP2C8**.



Purity: 98.09%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg

ACP-5862-d4

Cat. No.: HY-135334S

ACP-5862-d4 is deuterium labeled ACP-5862. ACP-5862 is a major active, circulating, pyrrolidine ring-opened metabolite of Acalabrutinib with an IC50 of 5.0 nM for Bruton tyrosine kinase (BTK).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

AMG-208

Cat. No.: HY-12035

AMG-208 is an orally active **c-Met/RON** dual selective inhibitor with an IC_{50} of 9 nM for c-Met. AMG-208 is a **CYP3A4** inhibitor with an IC_{50} of 32 μM. AMG-208 has anti-cancer activity.



Purity: 99.34%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

Antihistamine-1

Cat. No.: HY-100238

Antihistamine-1 is a **H1-antihistamine** (K_i=6.9 nM) with acceptable blood-brain barrier penetration and also an inhibitor of **CYP2D6** and **hERG channel** with IC_{50}s of 5.4 and 0.8 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

APD668

Cat. No.: HY-15565

APD668 is a potent, selective and orally active agonist of **G-protein coupled receptor GPR119**, with EC_{50}s of 2.7 nM and 33 nM for **hGPR119** and **rGPR119**, respectively.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Apigenin (4',5,7-Trihydroxyflavone; Apigenol; C.I. Natural Yellow 1)

Cat. No.: HY-N1201

Apigenin (4',5,7-Trihydroxyflavone) is a competitive **CYP2C9** inhibitor with a K_i of 2 μM.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

AS1810722

Cat. No.: HY-134772

AS1810722 is an orally active and potent **STAT6** inhibitor with an IC_{50} of 1.9 nM. AS1810722 shows a good profile of **CYP3A4** inhibition. AS1810722, a derivative of fused bicyclic pyrimidine, has the potential for allergic diseases such as asthma and atopic diseases research.



Purity: 98.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Atazanavir

(BMS-232632)

Cat. No.: HY-17367

Atazanavir (BMS-232632), a highly selective **HIV-1 protease** inhibitor, is the first protease inhibitor approved for once-daily administration. Atazanavir (BMS-232632) is a substrate and inhibitor of **CYP3A4**, and an inhibitor and inducer of **P-glycoprotein (P-gp)**.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Atazanavir sulfate

(BMS-232632 sulfate) Cat. No.: HY-17367A

Atazanavir (BMS-232632) sulfate, a highly selective **HIV-1 protease** inhibitor, is the first protease inhibitor approved for once-daily administration. Atazanavir sulfate is a substrate and inhibitor of **CYP3A4**, and an inhibitor and inducer of **P-glycoprotein (P-gp)**.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Atazanavir-d5

Cat. No.: HY-17367S3

Atazanavir-d5 is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective **HIV-1 protease** inhibitor, is the first protease inhibitor approved for once-daily administration.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Atazanavir-d6

(BMS-232632-d6) Cat. No.: HY-17367S4

Atazanavir-d6 is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Atazanavir-d9

(BMS-232632-d9) Cat. No.: HY-17367S2

Atazanavir-d9 (BMS-232632-d9) is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective **HIV-1 protease** inhibitor, is the first protease inhibitor approved for once-daily administration.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Atovaquone

(Atavaquone) Cat. No.: HY-13832

Atovaquone (Atavaquone) is a potent, selective and orally active inhibitor of the **parasite's mitochondrial cytochrome bc1 complex**.



Purity: 99.73%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Atovaquone (4-chlorophenyl-2,3,5,6-d4)

Cat. No.: HY-13832S1

Atovaquone (4-chlorophenyl-2,3,5,6-d4) is the deuterium labeled Atovaquone. Atovaquone is a potent, selective and orally active inhibitor of the **parasite's mitochondrial cytochrome bc1 complex**.



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 500 µg, 1 mg, 5 mg

Atovaquone-d5

(Atavaquone-d5) Cat. No.: HY-13832S2

Atovaquone-d5 (Atavaquone-d5) is the deuterium labeled Atovaquone. Atovaquone (Atavaquone) is a potent, selective and orally active inhibitor of the **parasite's mitochondrial cytochrome bc1 complex**.



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 1 mg, 5 mg

AZD7325

Cat. No.: HY-111052

AZD7325 is a potent and orally active partial selective PAM of **GABAAα2 and Aα3 receptor** (K_i=0.3 and 1.3 nM, respectively), and has less antagonistic efficacy at the Aα1 and Aα5 receptor subtypes.



Purity: 98.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bergamottin

(5-Geranoxypsoralen; Bergamotine; Bergaptin) Cat. No.: HY-N2194

Bergamottin is a potent and competitive **CYP1A1** inhibitor with a K_i of 10.703 nM.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Bergapten

(5-Methoxypsoralen) Cat. No.: HY-N0370

Bergapten is a natural anti-inflammatory and anti-tumor agent. Bergapten is inhibitory towards mouse and human **CYP** isoforms.



Purity: 99.96%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Bergapten-d3

(5-Methoxypsoralen-d3) Cat. No.: HY-N0370S

Bergapten-d3 is deuterium labeled Bergapten. Bergapten is a natural anti-inflammatory and anti-tumor agent. Bergapten is inhibitory towards mouse and human CYP isoforms.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bergaptol

(5-Hydroxypsoralen; 4-Hydroxybergapten) Cat. No.: HY-76316

Bergaptol is a hydroxylated psoralen that acts as a potent inhibitors of debenzylation activity of CYP3A4 enzyme with an IC50 value of 24.92 uM. Recent studies suggest that it may have antiproliferative and anticancer properties.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

BI 653048

Cat. No.: HY-12946

BI 653048 is a selective and orally active nonsteroidal **glucocorticoid (GC)** agonist with an IC_{50} value of 55 nM. BI 653048 inhibits CP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 isoforms' activity and reduces affinity for the hERG ion channel (IC_{50}>30 μM).



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

BI 653048 phosphate

Cat. No.: HY-12946A

BI 653048 phosphate is a selective and orally active nonsteroidal **glucocorticoid (GC)** agonist with an IC_{50} value of 55 nM.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

BI 689648

Cat. No.: HY-101217

BI 689648 is a novel, highly selective **aldosterone synthase** inhibitor which can inhibit **CYP11B1** and **CYP11B2** with IC_{50}s of 310 and 2.1 nM, respectively.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BMS-819881

Cat. No.: HY-12433

BMS-819881 is a melaninconcentrating hormone receptor 1 (**MCHR1**) antagonist, which binds rat MCHR1 with a K_i of 7 nM. BMS-819881 also is selective and potent for **CYP3A4** activity with an EC_{50} of 13 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMS-986202

Cat. No.: HY-131968

BMS-986202 is a potent, selective and orally active **Tyk2** inhibitor that binds to **Tyk2 JH2** with an IC_{50} of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members.



Purity: 99.46%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Bucolome

(Paramidin; Paramidine) Cat. No.: HY-U00048

Bucolome is a **CYP2C9** inhibitor, used as an uricosuric agent or anti-inflammatory agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BVT948

Cat. No.: HY-100625

BVT948 is a **protein tyrosine phosphatase** (**PTP**) inhibitor which can also inhibit several **cytochrome P450** (**P450**) isoforms and lysine methyltransferase **SETD8** (**KMT5A**).



Purity: 98.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Carbosulfan

Cat. No.: HY-B2015

Carbosulfan inhibited relatively potently CYP3A4 and moderately CYP1A1/2 and CYP2C19 in pooled HLM (human livers). Carbosulfan activation is predominantly catalyzed in humans by CYP3A4.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 500 mg

Carbosulfan-d18

Cat. No.: HY-B2015S

Carbosulfan-d18 is the deuterium labeled Carbosulfan. Carbosulfan inhibited relatively potently CYP3A4 and moderately CYP1A1/2 and CYP2C19 in pooled HLM (human livers). Carbosulfan activation is predominantly catalyzed in humans by CYP3A4.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Casopitant mesylate

(GW679769B)

Cat. No.: HY-14405A

Casopitant mesylate (GW679769B) is a potent, selective, brain permeable and orally active **neurokinin 1 (NK1) receptor** antagonist. Casopitant mesylate is a second in the class of antiemetics that acts to antagonise the emetogenic effect of substance P.



Purity: 99.83%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CDD3505

Cat. No.: HY-100901

CDD3505 is used for elevating high density lipoprotein cholesterol (HDL) by inducing hepatic **cytochrome P450IIIA (CYP3A)** activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CDD3506

Cat. No.: HY-100902

CDD3506 is used for elevating high density lipoprotein cholesterol (HDL) by inducing hepatic **cytochrome P450IIIA (CYP3A)** activity.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cecropin B

Cat. No.: HY-P0092

Cecropin B has high level of antimicrobial activity and is considered as a valuable peptide antibiotic.

Purity: 95.33%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg, 10 mg

Cedrol

((+)-Cedrol; α-Cedrol)

Cat. No.: HY-N2071

Cedrol is a bioactive sesquiterpene, a potent competitive inhibitor of **cytochrome P-450** (CYP) enzymes. Cedrol inhibits CYP2B6-mediated bupropion hydroxylase and CYP3A4-mediated midazolam hydroxylation with K_i of 0.9 μM and 3.4 μM, respectively.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Cephaeline dihydrochloride

((-)-Cephaeline dihydrochloride; NSC 32944)

Cat. No.: HY-N2260

Cephaeline dihydrochloride is a selective **CYP2D6** inhibtor with an IC_{50} of 121 μM.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Chlorzoxazone

Cat. No.: HY-B1462

Chlorzoxazone is a centrally acting muscle relaxant used to treat muscle spasm and the resulting pain or discomfort. It acts on the spinal cord by depressing reflexes.



Purity: 99.60%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g

Chlorzoxazone-d3

Cat. No.: HY-B1462S

Chlorzoxazone-d3 is the deuterium labeled Chlorzoxazone. Chlorzoxazone is a centrally acting muscle relaxant used to treat muscle spasm and the resulting pain or discomfort. It acts on the spinal cord by depressing reflexes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Cholesterol 24-hydroxylase-IN-1

Cat. No.: HY-144309

Cholesterol 24-hydroxylase-IN-1 (compound 17) is a potent, orally active, and highly selective **cholesterol 24-hydroxylase** (CH24H or CYP46A1) inhibitor (IC_{50}=8.5 nM). Cholesterol 24-hydroxylase-IN-1 can cross blood-brain barrier.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Chrysosplenetin

Cat. No.: HY-N1457

Chrysosplenetin is one of the polymethoxylated flavonoids in Artemisia annua L. (Compositae) and other several Chinese herbs. Chrysosplenetin inhibits **P-gp** activity and reverses the up-regulated P-gp and MDR1 levels induced by artemisinin (ART).



Purity: 99.52%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

cis-Atovaquone-d4

(cis-Atavaquone-d4)

Cat. No.: HY-13832S3

cis-Atovaquone-d4 is deuterium labeled Atovaquone. Atovaquone (Atavaquone) is a potent, selective and orally active inhibitor of the parasite's mitochondrial cytochrome bc1 complex. Atovaquone is against human and P.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Clarithromycin

Cat. No.: HY-17508

Clarithromycin has a broad spectrum of **antimicrobial** activity. Clarithromycin inhibits the **CYP3A4**-catalyzed triazolam alpha-hydroxylation with the IC_{50} (K_I) value of 56 (43) μM. Clarithromycin significantly inhibits the **HERG potassium current**.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Clobetasol propionate

Cat. No.: HY-13600

Clobetasol propionate is a potent and selective **CYP3A5** inhibitor with an IC_{50} of 0.206 μM. Clobetasol propionate has no inhibiting on CYP3A4 or other major CYPs. Clobetasol propionate is a corticosteroid and has the potential for psoriasis and other dermatoses research.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Clomethiazole

Cat. No.: HY-129105

Chlormethiazole is an potent and orally active $GABA_A$ agonist. Chlormethiazole inhibits cytochrome P450 isoforms: **CYP2A6** and **CYP2E1** in human liver microsomes. Chlormethiazole is an anticonvulsant agent and has the potential for treating convulsive status epilepticus.



Purity: 98.19%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 100 mg

Clopidogrel hydrogen sulfate ((S)-(+)-Clopidogrel bisulfate; (S)-(+)-Clopidogrel hydrogen sulfate)

Cat. No.: HY-17459

Clopidogrel hydrogen sulfate is an **antiplatelet** agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits **CYP2B6** and **CYP2C19** with IC_{50}s of 18.2 nM and 524 nM, respectively.



Purity: 99.75%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Cobicistat

(GS-9350)

Cat. No.: HY-10493

Cobicistat is a potent and selective inhibitor of **cytochrome P450 3A (CYP3A) enzymes** with IC_{50}s of 30-285 nM. Cobicistat is a pharmacokinetic enhancer which increases the overall absorption of several HIV medications.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Curcumenol

((+)-Curcumenol)

Cat. No.: HY-N2259

Curcumenol ((+)-Curcumenol) is a potent **CYP3A4** inhibitor with an IC_{50} of 12.6 μM, which is one of constituents in the plants of medicinally important genus of Curcuma zedoaria, with neuroprotection, anti-inflammatory, anti-tumor and hepatoprotective activities.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 100 mg

CYP11B2-IN-1

Cat. No.: HY-135281

CYP11B2-IN-1 is a **CYP11B2** inhibitor with an IC_{50} of 2.3 nM. CYP11B2-IN-1 inhibits CYP11B1 with an IC_{50} of 142 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CYP121A1-IN-1

Cat. No.: HY-144325

CYP121A1-IN-1 is a potent **CYP121A1** inhibitor with favorable activity against Mycobacterium tuberculosis (H37Rv MIC_{90}6.25 μM, 2.2 μg/mL).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CYP17-IN-1

Cat. No.: HY-101516

CYP17-IN-1 (compound 9c) is a potent and orally active **CYP17** inhibitor against rat and human CYP17 with **IC_{50}**s of 15.8 and 20.1 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CYP3cide

(PF-4981517)

Cat. No.: HY-18642

CYP3cide (PF-4981517) is a potent, selective and time-dependent inhibitor of **cytochrome P4503A4 (CYP3A4)**. The **IC_{50}** values for **Midazolam 1'-hydroxylase** activity are 0.03 μM, 17 μM, and 71 μM for **CYP3A4**, CYP3A5, and CYP3A7, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CYP51/HDAC-IN-1

Cat. No.: HY-144643

CYP51/HDAC-IN-1 is a potent, orally active **CYP51/HDAC** dual inhibitor. CYP51/HDAC-IN-1 inhibits important virulence factors and down-regulated resistance-associated genes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

D4-abiraterone

(Δ4-Abiraterone; CB-7627; Abiraterone D4A metabolite)

Cat. No.: HY-109619

D4-abiraterone is a major metabolite of abiraterone. D4-abiraterone is an inhibitor of **CYP17A1**, 3b-hydroxysteroid dehydrogenase (**3βHSD**) and steroid-5a-reductase (**SRD5A**) and also an antagonist of **androgen receptor**.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Dafadine-A

Cat. No.: HY-16670

Dafadine-A, an analog of dafadine, is a novel inhibitor of DAF-9 cytochrome P450 in the nematode Caenorhabditis elegans; also inhibits the mammalian ortholog of DAF-9(CYP27A1).



Purity: 98.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Dagrocorat

(PF-00251802)

Cat. No.: HY-16718

Dagrocorat (PF-00251802) is an orally active and selective high-affinity partial agonist of the **glucocorticoid receptor**.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Dagrocorat hydrochloride

(PF-00251802 hydrochloride)

Cat. No.: HY-16718A

Dagrocorat (PF-00251802) hydrochloride is an orally active and selective high-affinity partial agonist of the **glucocorticoid receptor**.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Dapaconazole

Cat. No.: HY-16719

Dapaconazole, as an antifungal agent, inhibits **sterol 14α-demethylase cytochrome P450** activity with an **IC_{50}** of 1.4 μM.



Purity: 98.95%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Dihydromethysticin

((+)-Dihydromethysticin)

Cat. No.: HY-N0921

Dihydromethysticin is one of the six major kavalactones found in the kava plant; has marked activity on the induction of CYP3A23.



Purity: 98.89%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Diosmetin

Cat. No.: HY-N0125

Diosmetin is a natural flavonoid which inhibits human **CYP1A** enzyme activity with an **IC_{50}** of 40 μM in HepG2 cell.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg

Diosmetin-d3

Cat. No.: HY-N0125S

Diosmetin-d3 is the deuterium labeled Diosmetin. Diosmetin is a natural flavonoid which inhibits human **CYP1A** enzyme activity with an IC_{50} of 40 μM in HepG2 cell.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

DMU2105

Cat. No.: HY-101284

DMU2105 is a potent and specific **CYP1B1** inhibitor, with IC_{50}s of 10 nM and 742 nM for CYP1B1 and CYP1A1, respectively.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

DMU2139

Cat. No.: HY-101285

DMU2139 is a potent and specific **CYP1B1** inhibitor, with IC_{50}s of 9 nM and 795 nM for CYP1B1 and CYP1A1, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Doxepin D3 Hydrochloride

Cat. No.: HY-B0725S

Doxepin D3 Hydrochloride is a deuterium labeled Doxepin Hydrochloride. Doxepin hydrochloride is an orally active tricyclic antidepressant. Doxepin hydrochloride is a potent and selective **histamine receptor H1** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Doxepin Hydrochloride

Cat. No.: HY-B0725

Doxepin hydrochloride is an orally active tricyclic antidepressant agent. Doxepin hydrochloride is a potent and selective **histamine receptor H1** antagonist. Doxepin hydrochloride is also a potent **CYP450** inhibitor and significantly inhibits **CYP450 2C19** and **1A2**.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g, 10 g

Dronedarone

(SR 33589)

Cat. No.: HY-A0016

Dronedarone (SR 33589), a derivative of amiodarone (HY-14187), is a class Ⅲ **antiarrhythmic agent** for the study of atrial fibrillation (AF) and atrial flutter.



Purity: 99.81%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Dronedarone D6 hydrochloride

Cat. No.: HY-A0016S

Dronedarone D6 hydrochloride is the deuterium labeled Dronedarone. Dronedarone hydrochloride, a derivative of Amiodarone (HY-14187), is a class Ⅲ **antiarrhythmic agent** for the study of atrial fibrillation (AF) and atrial flutter.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EMT inhibitor-2

Cat. No.: HY-128859

EMT inhibitor-2 (Compound 1) inhibits epithelial-mesenchymal transition (EMT) induced by substances such as IL-1β and TGF-β released from the immunocytes. EMT inhibitor-2 inhibits CYP3A4 testosteron and CYP2C9 with IC_{50}s of 49.72 and 5.54 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fenofibrate

Cat. No.: HY-17356

Fenofibrate is a selective **PPARα** agonist with an EC_{50} of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC_{50}s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for **CYP2C19**, **CYP2B6**, **CYP2C9**, **CYP2C8**, and **CYP3A4**, respectively.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 5 g, 10 g

Fenofibrate-d6

Cat. No.: HY-17356S

Fenofibrate-d6 is the deuterium labeled Fenofibrate. Fenofibrate is a selective **PPARα** agonist with an EC_{50} of 30 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fipronil

Cat. No.: HY-B0822

Fipronil is an insecticide that acts as a selective antagonist of **insect GABA receptors** (IC_{50}s = 30 nM and 1,600 nM for **cockroach** and **rat receptors**, respectively).



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Fomepizole

(4-Methylpyrazole)

Cat. No.: HY-B0876

Fomepizole (4-Methylpyrazole) is a potent **cytochrome P450 (CYP2E1)** inhibitor. Fomepizole is a competitive inhibitor of the enzyme **alcohol dehydrogenase**. Fomepizole blocks further conversion of methanol and ethylene glycol to toxic metabolites.



Purity: 99.67%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Fraxinol

Cat. No.: HY-N2372

Fraxinol is isolated from Lobelia chinensis.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Friedelin

Cat. No.: HY-N4110

Friedelin is isolated from isolated from the leaves of Maytenus ilicifolia(Mart).
Friedelin is a noncompetitive inhibitor of **CYP3A4** with IC_{50} and $K_i$values of 10.79 μM and 6.16 μM, respectively.



Purity: ≥98.00%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Furafylline

Cat. No.: HY-107204

Furafylline is a potent and selective inhibitor of **human cytochrome P450IA2** with an IC_{50} of 0.07 μM.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Galangin

(Norizalpinin; 3,5,7-Trihydroxyflavone)

Cat. No.: HY-N0382

Galangin (Norizalpinin) is an agonist/antagonist of the arylhydrocarbon receptor. Galangin (Norizalpinin) also shows inhibition of **CYP1A1** activity.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Galangin-13C3

Cat. No.: HY-N0382S

Galangin-13C3 is the 13C-labeled Galangin.
Galangin (Norizalpinin) is an agonist/antagonist of the arylhydrocarbon receptor. Galangin (Norizalpinin) also shows inhibition of **CYP1A1** activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Galeterone

(TOK-001; VN-124-1)

Cat. No.: HY-70006

Galeterone (TOK-001) is a multifunctional antiandrogen and **CYP17** inhibitor (IC_{50}=47 nM) in castration resistant prostate cancer (CRPC).



Purity: 99.90%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Gemfibrozil

(CI-719)

Cat. No.: HY-B0258

Gemfibrozil is an activator of **PPAR-α**, used as a lipid-lowering drug; Gemfibrozil is also a nonselective inhibitor of several **P450** isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Gemfibrozil 1-O-β-glucuronide

Cat. No.: HY-129993

Gemfibrozil 1-O-β-Glucuronide, a metabolite of Gemfibrozil (CI-719; HY-B0258), is a potent and competitive **P450 (CYP)** isoform CYP2C8 inhibitor with an IC_{50} of 4.07 μM.



Purity: 96.99%
Clinical Data: No Development Reported
Size: 1 mg

Gemfibrozil-d6

(CI-719-d6) Cat. No.: HY-B0258S

Gemfibrozil-d6 (CI-719-d6) is the deuterium labeled Gemfibrozil.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 50 mg

Gentiopicroside

(Gentiopicrin) Cat. No.: HY-N0494

Gentiopicroside, a naturally occurring iridoid glycoside, inhibits **P450** activity, with an IC_{50} and a K_i of 61 μM and 22.8 μM for CYP2A6; Gentiopicroside has antianti-inflammatoryand antioxidative effects.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Ginsenoside C-K

(Ginsenoside compound K; Ginsenoside K) Cat. No.: HY-N0904

Ginsenoside C-K, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects by reducing **iNOS** and **COX-2**. Ginsenoside C-K exhibits an inhibition against the activity of **CYP2C9** and **CYP2A6** in human liver microsomes with **IC_{50}**s of 32.0±3.6 μM and 63.6±4.2 μM, respectively.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside F1

(20(S)-Ginsenoside F1) Cat. No.: HY-N0598

Ginsenoside F1, an enzymatically modified derivative of Ginsenoside Rg1, demonstrates competitive inhibition of **CYP3A4** activity and weaker inhibition of CYP2D6 activity.



Purity: 98.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Ginsenoside Rd

(Gypenoside VIII) Cat. No.: HY-N0043

Ginsenoside Rd inhibits TNFα-induced **NF-κB** transcriptional activity with an **IC_{50}** of 12.05±0.82 μM in HepG2 cells. Ginsenoside Rd inhibits expression of **COX-2** and **iNOS** mRNA. Ginsenoside Rd also inhibits **Ca^{2+}** influx.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

GSK2945

Cat. No.: HY-117147

GSK2945 is a class of tertiary amine, and is a highly specific **Rev-erbα/REV-ERBα (mouse/human reverse erythroblastosis virus α)** antagonist with **EC_{50}**s of 21.5 μM and 20.8 μM, respectively. GSK2945 enhances **cholesterol 7α-hydroxylase (CYP7A1)** level and cholesterol metabolism.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK2945 hydrochloride

Cat. No.: HY-117147A

GSK2945 hydrochloride is a class of tertiary amine, and is a highly specific **Rev-erbα/REV-ERBα (mouse/human reverse erythroblastosis virus α)** antagonist with **EC_{50}**s of 21.5 μM and 20.8 μM, respectively.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GYKI-47261 dihydrochloride

Cat. No.: HY-19435A

GYKI-47261 dihydrochloride is a competitive, orally active, and selective **AMPA receptor** antagonist with an **IC_{50}** of 2.5 μM. GYKI-47261 has broad spectrum anticonvulsive activity and neuroprotective effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HET0016

Cat. No.: HY-124527

HET0016 is a potent and selective **20-hydroxyeicosatetraenoic acid (20-HETE)** synthase inhibitor, with **IC_{50}** values of 17.7 nM, 12.1 nM and 20.6 nM for recombinant CYP4A1-, CYP4A2- and CYP4A3-catalyzed 20-HETE synthesis, respectively.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IHMT-PI3Kδ-372

Cat. No.: HY-131910

IHMT-PI3Kδ-372 is a potent and selective **PI3Kδ** inhibitor with an **IC_{50}** of 14 nM. IHMT-PI3Kδ-372 shows high selectivity over other class I PI3Ks (5683 fold) and other protein kinases. IHMT-PI3Kδ-372 can be uesd for chronic obstructive pulmonary disease (COPD) research.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Inz-1

Cat. No.: HY-116686

Inz-1 is a potent and selective **mitochondrial cytochrome bc1** inhibitor for yeast (IC_{50}=8.092 μM) over humans (IC_{50}=45.320 μM). Inz-1 reverses Fluconazole (HY-B0101) or other triazole antifungals' resistance in the pathogenic fungus Candida albicans.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Isavuconazole

(BAL-4815; RO-0094815)

Cat. No.: HY-14273

Isavuconazole (BAL-4815) is a triazole prodrug with antifungal activity against yeasts, molds, and dimorphic fungi. Isavuconazole inhibits ergosterol biosynthesis and results in the disruption of fungal membrane structure and function.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Isavuconazole-d4

(BAL-4815-d4; RO-0094815-d4)

Cat. No.: HY-14273S

Isavuconazole D4 (BAL-4815 D4) is a deuterium labeled Isavuconazole (BAL-4815). Isavuconazole is a triazole prodrug with antifungal activity against yeasts, molds, and dimorphic fungi.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Isoglycycoumarin

Cat. No.: HY-N6989

Isoglycycoumarin is a flavonoid isolated from the roots of Glycyrrhiza uralensis. Isoglycycoumarin is a highly selective probe for human cytochrome **P450 2A6 (CYP2A6)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Isosilybin

(Isosilybinin)

Cat. No.: HY-N0779

Isosilybin (Isosilybinin) is a flavonoid from milk thistle; inhibits **CYP3A4** induction with an IC_{50} of 74 μM.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Itraconazole

(R51211)

Cat. No.: HY-17514

Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active **Hedgehog (Hh) signaling pathway** antagonist with an IC_{50} of ~800 nM.



Purity: 99.15%
Clinical Data: Launched
Size: 100 mg, 500 mg

Itraconazole-d5

Cat. No.: HY-17514S

Itraconazole-d5 (R51211-d5) is the deuterium labeled Itraconazole. Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active **Hedgehog (Hh) signaling pathway** antagonist with an IC_{50} of ~800 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg

K777

Cat. No.: HY-119293

K777 is a potent, orally active and irreversible **cysteine protease** inhibitor. K777 is also a potent **CYP3A4** inhibitor with an IC_{50} of 60 nM and a selective **CCR4** antagonist featuring the potent chemotaxis inhibition.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ketoconazole

(Ketoconazol; R 41400)

Cat. No.: HY-B0105

Ketoconazole (R-41400) is an imidazole anti-fungal agent, a CYP3A4 and CYP24A1 inhibitor.



Purity: 99.47%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 1 g, 5 g

Ketoconazole-d4

(Ketoconazol-d4; R 41400-d4)

Cat. No.: HY-B0105S1

Ketoconazole-d4 (Ketoconazol-d4) is the deuterium labeled Ketoconazole. Ketoconazole (R-41400) is an imidazole anti-fungal agent, a CYP3A4 and CYP24A1 inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ketoconazole-d8

Cat. No.: HY-B0105S

Ketoconazole-d8 is the deuterium labeled Ketoconazole. Ketoconazole (R-41400) is an imidazole anti-fungal agent, a CYP3A4 and CYP24A1 inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 25 mg

Kushenol K

Cat. No.: HY-117010

Kushenol K, a flavonoid antioxidant isolated from the roots of Sophora flavescens. Kushenol K is a **cytochrome P-450 3A4 (CYP3A4)** inhibitor with a K_i value of 1.35 μM. Kushenol K shows weak antiviral activity against **HSV-2** (EC_{50} of 147 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Kushenol M

Cat. No.: HY-N8094

Kushenol M is a flavonoid from Sophora flavescens. Kushenol M is a **cytochrome P450 (CYP)** inhibitor, with IC_{50} values of 1.29 μM for CYP3A4 in human liver microsomes.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Liarozole

(R75251)

Cat. No.: HY-106019

Liarozole (R75251; R85246) is an imidazole derivative and orally active **retinoic acid (RA) metabolism-blocking agent (RAMBA)**.



Purity: 98.52%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Liarozole dihydrochloride

(R75251 dihydrochloride)

Cat. No.: HY-106019C

Liarozole (R75251) dihydrochloride is an imidazole derivative and orally active **retinoic acid (RA) metabolism-blocking agent (RAMBA)**.



Purity: 98.66%
Clinical Data: Phase 3
Size: 1 mg

Linderane

Cat. No.: HY-N0688

Linderane, isolated from the root of Lindera strychnifolia, is an irreversible inhibitor **cytochrome P450 2C9 (CYP2C9)**. Linderane has the potential to relieve pain and cramp.



Purity: 98.86%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

LKY-047

Cat. No.: HY-117026

LKY-047, a Decursin derivative, is a potent and selective reversible competitive **cytochrome P45022J2 (CYP2J2)** inhibitor with an IC_{50} of 1.7 μM. LKY-047 is inactive against other human P450s, such as CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MCH-1 antagonist 1

Cat. No.: HY-100331

MCH-1 antagonist 1 is a potent melanin concentrating hormone (**MCH-1**) antagonist with a K_i of 2.6 nM. MCH-1 antagonist 1 also inhibits **CYP3A4** with an IC_{50} of 10 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mefentrifluconazole

Cat. No.: HY-136063

Mefentrifluconazole is a novel azole derivative and used as an agrochemical broad-spectrum **antifungal agent**. Mefentrifluconazole is a potent, selective and orally active fungal **CYP51** (K_d= 0.5 nM) inhibitor, but shows less inhibitory activity on human aromatase (IC_{50}=0.92 μM).



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Mephenytoin

Cat. No.: HY-B1184

Mephenytoin, an anticonvulsant, is the CYP2C19 and CYP2B6 substrate.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Mephenytoin-d3

Cat. No.: HY-B1184S

(Rac)-Mephenytoin-d3 is a labelled racemic Mephenytoin. Mephenytoin, an anticonvulsant, is the CYP2C19 and CYP2B6 substrate.



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 25 mg

Mephenytoin-d5

Cat. No.: HY-B1184S1



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Methoxsalen

(8-Methoxypsoralen; Xanthotoxin; 8-MOP)

Cat. No.: HY-30151

Methoxsalen (8-Methoxypsoralen) is a potent tricyclic furocoumarin suicide inhibitor of CYP (cytochrome P-450), is an agent used to treat psoriasis, eczema, vitiligo and some cutaneous Lymphomas in conjunction with exposing the skin to sunlight.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Methysticin

(DL-Methysticin; (±)-Methystici)

Cat. No.: HY-N0922

Methysticin is a major kavalactone in kava extract to induce **CYP1A1**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Metyrapone

(Su-4885)

Cat. No.: HY-B1232

Metyrapone is an inhibitor of cytochrome P450-mediated ω/ω-1 hydroxylase activity and CYP11B1. Target: CYP11B1 Metyrapone is a drug used in the diagnosis of adrenal insufficiency and occasionally in the treatment of Cushing's syndrome (hypercortisolism).



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

MS-PPOH

Cat. No.: HY-114759

MS-PPOH is a potent and selective **cytochrome P450 (CYP) epoxygenase** inhibitor. MS-PPOH inhibits **CYP2C8** and **CYP2C9** with IC_{50}s of 15 and 11 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

N-Desmethyl-Apalutamide

Cat. No.: HY-135331

N-Desmethyl Apalutamide is an active metabolite of Apalutamide. N-Desmethyl Apalutamide is a less potent antagonist of the **androgen receptor** and is responsible for one-third of the activity of Apalutamide.



Purity: 97.24%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Nornuciferine

Cat. No.: HY-N2129

N-Nornuciferine is an aporphine alkaloid in lotus leaf that significantly inhibits **CYP2D6** with IC_{50} and K_i of 3.76 and 2.34 μM, respectively.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Nampt-IN-5

Cat. No.: HY-130606

Nampt-IN-5 is a potent **nicotinamide phosphoribosyltransferase (NAMPT)** inhibitor. Nampt-IN-5 also inhibits CYP3A4 activity and has cellular IC_{50}s of 0.7 nM and 3.9 nM against A2780 and COR-L23, respectively.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Naringin

(Naringoside)

Cat. No.: HY-N0153

Naringin is a major flavanone glycoside obtained from tomatoes, grapefruits, and many other citrus fruits. Naringin exhibits biological properties such as antioxidant, anti-inflammatory, and antiapoptotic activities.



Purity: 98.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 200 mg, 10 g

Nav1.7-IN-8

Cat. No.: HY-141547

Nav1.7-IN-8 is a potent blockage of **NaV1.7** with high selectivity for the inhibition of **NaV1.7** over the subtypes hNaV1.1 and hNaV1.5. Nav1.7-IN-8 inhibits **CYP2C9** and **CYP3A4** with an IC_{50} of 0.17 μM and 0.077 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ODM-204

Cat. No.: HY-111421

ODM-204 is novel nonsteroidal dual inhibitor of both **androgen receptor** and **CYP17A1 enzyme**, with IC_{50}s of 80 nM and 22 nM, respectively.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Olivetol

Cat. No.: HY-W008364

Olivetol is a naturally phenol found in lichens and produced by certain insects, acting as a competitive inhibitor of the cannabinoid receptors **CB1** and **CB2**. Olivetol also inhibits **CYP2C19** and **CYP2D6** activity, with IC_{50}s of 15.3 μM, 7.21 μM and K_is of 2.71 μM, 2.87 μM, respectively.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Orteronel

(TAK-700)

Cat. No.: HY-10505

Orteronel (TAK-700) is a highly selective inhibitor of human **17,20-lyase (CYP17)** with IC_{50} of 38 nM, and exhibits >1000-fold selectivity over other CYPs such as 11-hydroxylase and CYP3A4.



Purity: 99.46%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Oteseconazole

(VT-1161)

Cat. No.: HY-17643

Oteseconazole (VT-1161) is an orally active **anti-fungal** agent, potently binds to and inhibits Candida albicans **CYP51** (K_d, <39 nM), shows no obvious effect on human CYP51.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

PC945

Cat. No.: HY-117766

PC945, a potent, long-acting **antifungal** triazole, possesses activity against a broad range of both azole-susceptible and azole-resistant strains of Aspergillus fumigatus.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Phillyrin

Cat. No.: HY-N0482

Phillyrin is isolated from Forsythia suspensa Vahl (Oleaceae), has antibacterial and anti-inflammatory activities. Phillyrin has potential inductive effects on rat **CYP1A2** and **CYP2D1** activities, without affecting CYP2C11 and CYP3A1/2 activities.



Purity: 98.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Phloracetophenone (2,4,6-trihydroxyacetophenone; 1-(2,4,6-Trihydroxyphenyl)ethanone)

Cat. No.: HY-W008226

Phloracetophenone (2,4,6-trihydroxyacetophenone) is the aglycone part of acetophenone glycoside obtained from Curcuma comosa Roxb, with cholesterol-lowering activity. Phloracetophenone enhances cholesterol 7α-hydroxylase (**CYP7A1**) activity.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Phortress

(NSC 710305)

Cat. No.: HY-103223

Phortress is a high affinity **AhR** ligand that elicits antitumor activity by inducing transcription of CYP1A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Phortress free base

Cat. No.: HY-128920

Phortress free base (NSC 710305) is a P450 **CYP1A1**-activated antitumor prodrug with antitumor activity. Phortress free base leads to DNA damage and cell cycle arrest.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Piperonylic acid

Cat. No.: HY-41404

Piperonylic acid is a natural molecule bearing a methylenedioxy function that closely mimics the structure of trans-cinnamic acid. Piperonylic Acid is a selective, mechanism-based inactivator of the trans-cinnamate 4-Hydroxylase.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 500 mg

Polygalaxanthone III

Cat. No.: HY-N1407

Polygalaxanthone III is extracted from polygala tenuifolia wild, has inhibitory effect towards **CYP450** enzyme. Polygalaxanthone III inhibits chlorzoxazone 6-hydroxylation catalyzed by CYP2E1 with an IC_{50} of 50.56 μM.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Pradefovir mesylate

(Remofovir mesylate)

Cat. No.: HY-112690A

Pradefovir mesylate is a good substrate for liver CYP3A4. Pradefovir is converted to 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in human liver microsomes with a K_m of 60 μM.



Purity: 99.89%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Pregnenolone 16α-carbonitrile

Cat. No.: HY-131723

Pregnenolone 16α-carbonitrile is an orally active prototypical and effective rodent-PXR activator. Pregnenolone 16α-carbonitrile, a synthetic steroid, induces cytochrome P450 3A expression. Pregnenolone 16α-carbonitrile exhibits increased resistance to subsequent stressful insults.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Proadifen hydrochloride

(SKF-525A; U-5446; RP-5171)

Cat. No.: HY-B1311

Proadifen hydrochloride is a Cytochrome P450 inhibitor (IC50 = 19μM).



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 250 mg, 500 mg

Pyributicarb

(TSH-888)

Cat. No.: HY-111202

Pyributicarb, a carbamate-type herbicide, is a potent activator of both **CYP3A4** gene and human **pregnane X receptor** (**hPXR**).



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

Quilseconazole

(VT-1129)

Cat. No.: HY-109040

Quilseconazole (VT-1129) is a potent, orally active **fungal Cyp51 (lanosterol 14-α-demethylase)** inhibitor, binds tightly to cryptococcal CYP51, but weakly inhibits humans CYP450 enzymes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Quinidine sulfate dihydrate

Cat. No.: HY-B1751D

Quinidine sulfate dihydrate is a potent and selective inhibitor of **cytochrome P450db** and inhibits amphetamine metabolism in vivo.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg

Ranitidine

Cat. No.: HY-B0693

Ranitidine is a potent, selective and orally active **histamine H2-receptor** antagonist with an IC_{50} of 3.3 μM that inhibits gastric secretion. Ranitidine is a weak inhibitor of **CYP2C19** and **CYP2C9**.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Ranitidine hydrochloride

Cat. No.: HY-B0281A

Ranitidine hydrochloride is a potent, selective and orally active **histamine H2-receptor** antagonist with an IC_{50} of 3.3 μM that inhibits gastric secretion. Ranitidine hydrochloride is a weak inhibitor of **CYP2C19** and **CYP2C9**.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Ranitidine-d6 hydrochloride

Cat. No.: HY-B0281AS

Ranitidine-d6 hydrochloride is the deuterium labeled Ranitidine hydrochloride. Ranitidine hydrochloride is a potent, selective and orally active **histamine H2-receptor** antagonist with an IC_{50} of 3.3 μM that inhibits gastric secretion.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Resorufin methyl ether

(Methoxyresorufin)

Cat. No.: HY-D0144

Resorufin methyl ether (Methoxyresorufin) is a cytochrome P450 fluorometric substrate. Resorufin methyl ether is a relatively specific substrate for CYP1A2 activity in rodents.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Revexepride

Cat. No.: HY-U00373

Revexepride is a highly selective **5-HT4 receptor** agonist, and a potential inducer of **CYP3A4 enzyme**, used for the treatment of gastroesophageal reflux disease.



Purity: 95.81%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RG-12525

(NID 525)

Cat. No.: HY-101676

RG-12525 is a a specific, competitive and orally effective antagonist of the **peptidoleukotrienes**, **LTC4**, **LTD4** and **LTE4**, inhibiting LTC4-, LTD4- and LTE4-inducd guinea pig parenchymal strips contractions, with IC_{50}s of 2.6 nM, 2.5 nM and 7 nM, respectively; RG-12525 is also a...



Purity: 98.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Rhapontigenin

Cat. No.: HY-N2229

Rhapontigenin is a natural analog of resveratrol with anticancer, antioxidant, antifungal and antibacterial activities. Rhapontigenin is amechanism-based, potent and selective **cytochrome P450 1A1** inactivator (IC_{50} = 400 nM).



Purity: 99.66%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

RO6889678

Cat. No.: HY-124364

RO6889678 is a highly potent **HBV** capsid formation inhibitor with a complex absorption, distribution, metabolism, and excretion (ADME) profile. RO6889678 is a potent inducer of CYP3A4 and coregulated proteins in human hepatocytes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Roquefortine C

Cat. No.: HY-N6748

Roquefortine C, a fungal cyclopeptide isolated from Penicillium roquefortii, activates **P-gp** and also inhibits **P450-3A** and other haemoproteins. Roquefortine C has bacteriostatic activities against Gram-positive bacteria.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg

S-(N-PhenethylthiocarbaMoyl)-L-cysteine

(PEITC-Cys)

Cat. No.: HY-115754

S-(N-PhenethylthiocarbaMoyl)-L-cysteine (PEITC-Cys), an **anticarcinogenic** agent, has antileukemic activity. S-(N-PhenethylthiocarbaMoyl)-L-cysteine inhibits DNA synthesis in HL60 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Salvianolic acid C

Cat. No.: HY-N0319

Salvianolic acid C is a noncompetitive Cytochrome P4502C8 (**CYP2C8**) inhibitor and a moderate mixed inhibitor of Cytochrome P45022J2 (**CYP2J2**), with K_is of 4.82 μM and 5.75 μM for CYP2C8 and CYP2J2, respectively.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Schisandrin A

(Schizandrin-A; Wuweizisu-A; Deoxyschizandrin)

Cat. No.: HY-N0693

Schisandrin A inhibits **CYP3A** activity with an IC_{50} of 6.60 μM and K_i of 5.83 μM, respectively.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Schisandrol B

(Gomisin-A; TJN-101; Wuweizi alcohol-B)

Cat. No.: HY-N0692

Schisandrol B (Gomisin-A) is a major active constituent of Schisandra sphenanthera with hepato-protective effects. Schisandrol B inhibits **reactive oxygen species (ROS)** production.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

SDZ285428

Cat. No.: HY-108938

SDZ285428 is a **CYP51** inhibitor. SDZ285428 inhibits Trypanosoma cruzi (TC) CYP51 with I/E2 <1 (5 min) and I/E2=9 (1 h). SDZ285428 inhibits Trypanosoma brucei (TB) CYP51 with I/E2 <1 (5 min) and I/E2=35 (1 h).



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Seneciphylline

Cat. No.: HY-N1282

Seneciphylline is a toxic pyrrolizidine alkaloid in Senecio plants. Seneciphylline significantly increases the activities of **epoxide hydrase** and **glutathione-S-transferase** but causes reduction of **cytochrome P-450** and related monooxygenase activities.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Seviteronel

(VT-464)

Cat. No.: HY-15996

Seviteronel (VT-464) is a potent CYP17 lyase inhibitor(h-Lyase IC_{50}=69 nM) that demonstrated both exceptional in vitro lyase/hydroxylase selectivity (~10-fold) and oral activity in a hamster model of androgen biosynthesis inhibition.



Purity: 99.85%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Seviteronel racemate

(VT-464 (racemate))

Cat. No.: HY-15996B

Seviteronel racemate (VT-464 racemate) is the racemate form of Seviteronel (VT-464), which is a potent CYP17 lyase inhibitor(h-Lyase IC_{50}=nM)inhibition.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Soticlestat

(TAK-935; OV935)

Cat. No.: HY-109123

Soticlestat (TAK-935; OV935) is a first-in-class, potent, selective, and orally active **cholesterol 24-hydroxylase (CH24H)** inhibitor. Soticlestat has the potential for epilepsy syndromes research.



Purity: 99.25%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SR9186

(ML368)

Cat. No.: HY-120696

SR9186 (ML368) is a potent **CYP3A4** inhibitor with IC_{50} s for inhibition of midazolam 1'hydroxymidazolam, testosterone 6β-hydroxytestosterone, and vincristine vincristine M1 of 9, 4, and 38 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Stiripentol

(BCX2600)

Cat. No.: HY-103392

Stiripentol (STP) is an anticonvulsant agent, which can inhibit **N-demethylation of CLB to NCLB** mediatated by CYP3A4 (noncompetitively) and CYP2C19 (competitively) with K_i of 1.59±0.07 and 0.516±0.065 μM and IC_{50} of 1.58 and 3.29 μM, respectively.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Stiripentol-d9

Cat. No.: HY-103392S

Stiripentol-d9 (BCX2600-d9) is the deuterium labeled Stiripentol.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Talarozole

(R115866)

Cat. No.: HY-14531

Talarozole (R115866) is an oral systemic all-trans **retinoic acid metabolism blocking agent (RAMBA)** which increases intracellular levels of endogenous all-trans retinoic acid (RA). Talarozole inhibits both **CYP26A1** and **CYP26B1** with IC_{50}s of 5.4 and 0.46 nM, respectively.



Purity: 99.78%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Talarozole (R enantiomer)

((R)-Talarozole) Cat. No.: HY-14802

Talarozole R enantiomer is a potent and selective inhibitor of cytochrome P450 26-mediated breakdown of endogenous all-trans retinoic acid for the treatment of psoriasis and acne.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tebuconazole

Cat. No.: HY-B0852

Tebuconazole is an agricultural azole fungicide which can also inhibit **CYP51** with IC_{50}s of 0.9 and 1.3 μM for Candida albicans CYP51 (**CaCYP51**) and truncated Homo sapiens CYP51 (**Δ60HsCYP51**), respectively.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 200 mg, 1 g

Tebuconazole-d9

Cat. No.: HY-B0852S

Tebuconazole-d9 is the deuterium labeled Tebuconazole. Tebuconazole is an agricultural azole fungicide which can also inhibit **CYP51** with IC_{50}s of 0.9 and 1.3 μM for Candida albicans CYP51 (**CaCYP51**) and truncated Homo sapiens CYP51 (**Δ60HsCYP51**), respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Tetrahydrocurcumin

(HZIV 81-2) Cat. No.: HY-N0893

Tetrahydrocurcumin is a Curcuminoid found in turmeric (Curcuma longa) that is produced by the reduction of Curcumin. Tetrahydrocurcumin inhibit **CYP2C9** and **CYP3A4**.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tetrahydrocurcumin D6

(HZIV 81-2 D6) Cat. No.: HY-N0893S

Tetrahydrocurcumin D6 (HZIV 81-2 D6) is a deuterium labeled Tetrahydrocurcumin. Tetrahydrocurcumin is a Curcuminoid which displays inhibitory activity for CYP2C9 and CYP3A4.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tetrahydropiperine

Cat. No.: HY-N4205

Tetrahydropiperine, a cyclohexyl analogue of piperine, is the first natural aryl pentanamide from Piper longum. Tetrahydropiperine (compound 14) inhibits the cytochrome P450 (CYP) isoform **CYP1A1/arylhydrocarbon hydroxylase** (AHH; IC_{50}=23 μM).



Purity: 99.45%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Thermopsoside

Cat. No.: HY-N6023

Thermopsoside is a flavone derivative isolated from Aspalathus linearis. Thermopsoside exhibits inhibitory effects on CYP450 isozymes with IC_{50} values of 6.0 μM, 9.5 μM, 12.0 μM, 32.0 μM, for CYP3A4, CYP2C19, CYP2D6 and CYP2C9, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Ticlopidine

(PCR 5332) Cat. No.: HY-100386

Ticlopidine (PCR 5332), an antithrombotic prodrug, acts as an allosteric, noncompetitive inhibitor of **CD39** with the IC_{50} of 81.7μM. Ticlopidine blocks several **NTPDase** isoenzymes with IC_{50}s of 170μM and 149μM for NTPDase2 and NTPDase3, respectively.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Ticlopidine-d4

(PCR 5332-d4) Cat. No.: HY-100386S

Ticlopidine-d4 (PCR 5332-d4) is the deuterium labeled Ticlopidine. Ticlopidine (PCR 5332), an antithrombotic prodrug, acts as an allosteric, noncompetitive inhibitor of **CD39** with the IC_{50} of 81.7μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 25 mg

TMS

((E)-2,3',4,5'-tetramethoxystilbene) Cat. No.: HY-19340

TMS ((E)-2,3',4,5'-tetramethoxystilbene) is a selective and competitive **CYP1B1** inhibitor with an IC_{50} of 6 nM and a K_i value of 3 nM. TMS shows a lesser extent inhibitory effect on CYP1A1 (IC_{50} = 300 nM) and CYP1A2 (IC_{50} = 3.1 μM).



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Topiroxostat

(FYX-051) Cat. No.: HY-14874

Topiroxostat (FYX-051) is a potent and orally active **xanthine oxidoreductase (XOR)** inhibitor with an IC_{50} value of 5.3 nM and a K_i value of 5.7 nM. Topiroxostat exhibits weak **CYP3A4**-inhibitory activity (18.6%). Topiroxostat has the potential for hyperuricemia treatment.



Purity: 99.68%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Topiroxostat-d4

(FYX-051-d4) Cat. No.: HY-14874S

Topiroxostat-d4 is deuterium labeled Topiroxostat. Topiroxostat (FYX-051) is a potent and orally active xanthine oxidoreductase (XOR) inhibitor with an IC50 value of 5.3 nM and a Ki value of 5.7 nM. Topiroxostat exhibits weak CYP3A4-inhibitory activity (18.6%).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Troleandomycin

(Triacetyloleandomycin) Cat. No.: HY-108881

Troleandomycin (Triacetyloleandomycin), a macrolide acrolide antibiotic, is a selective **CYP3A** inhibitor. Troleandomycin is an oral corticosteroid for asthma study.



Purity: ≥97.0%
Clinical Data: Launched
Size: 1 mg, 5 mg

Uniconazole

Cat. No.: HY-B0873

Uniconazole is a plant growth regulator that functions by inhibiting **cytochrome P450 707As** (K_i=68 nM), a family of enzymes that catabolize Abscisic acid, and thus, suppress gibberellin and sterol biosynthesis.



Purity: 98.81%
Clinical Data: No Development Reported
Size: 500 mg, 1 g

Veledimex (S enantiomer)

(INXN-1001 (S enantiomer); RG-115932 (S enantiomer)) Cat. No.: HY-16785B

Veledimex S enantiomer (INXN-1001 S enantiomer) is the S enantiomer of veledimex. Veledimex is an oral activator ligand for a proprietary gene therapy promoter system, and a moderate inhibitor of and substrate for **CYP3A4/5**.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Veledimex racemate

(INXN-1001 racemate; RG-115932 racemate) Cat. No.: HY-16785A

Veledimex racemate (INXN-1001 racemate) is the racemate of veledimex. Veledimex is an orally available, small-molecule activator ligand for the RheoSwitch Therapeutic System.



Purity: 97.82%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Verapamil

((±)-Verapamil; CP-16533-1) Cat. No.: HY-14275

Verapamil ((±)-Verapamil) is a **calcium channel** blocker and a potent and orally active first-generation **P-glycoprotein (P-gp)** inhibitor. Verapamil also inhibits **CYP3A4**. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research.



Purity: 99.96%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 50 mg

Verapamil EP Impurity C hydrochloride

(NSC-609249 hydrochloride) Cat. No.: HY-136589

NSC-609249 hydrochloride is an **impurity** of Verapamil (HY-14275). Verapamil is a **calcium channel** blocker and a potent and orally active first-generation **P-glycoprotein (P-gp)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Verapamil hydrochloride

((±)-Verapamil hydrochloride; CP-16533-1 hydrochloride) Cat. No.: HY-A0064

Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a **calcium channel** blocker and a potent and orally active first-generation **P-glycoprotein (P-gp)** inhibitor. Verapamil hydrochloride also inhibits **CYP3A4**.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Verapamil-d3 hydrochloride ((±)-Verapamil-d3 hydrochloride; CP-16533-1-d3 hydrochloride)

Cat. No.: HY-A0064S

Verapamil-d3 ((±)-Verapamil-d3) hydrochloride is the deuterium labeled Verapamil hydrochloride. Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a **calcium channel** blocker and a potent and orally active first-generation **P-glycoprotein (P-gp)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

α-Terpinyl acetate

Cat. No.: HY-N7136

α-Terpinyl acetate is a monoterpene ester isolated from Laurus nobilis L. essential oil. α-Terpinyl acetate is a competitive **P450 2B6** substrate which binding to the active site of P450 2B6 with a K_d value of 5.4 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

β-Amyrenonol

(11-Oxo-β-amyrin)

Cat. No.: HY-N2920

β-Amyrenonol (11-Oxo-β-amyrin), an oleanolic-type triterpenoid in licorice roots, is a precursor of Glycyrrhetinic acid. β-Amyrenonol has anti-proliferative and anti-inflammatory activities, and β-Amyrenonol could function as the skeleton for the synthesis of many triterpenoids.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

β-Apo-8'-carotenal

(Apocarotenal)

Cat. No.: HY-N6677

β-Apo-8'-carotenal (Apocarotenal), a provitamin A carotenoid, is an inducer of **CYPIA1** and **CYPIA2** in rat. β-Apo-8'-carotenal is present in many fruits and vegetables.



Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 100 mg

ε-Viniferin

(epsilon-Viniferin)

Cat. No.: HY-N3841

ε-Viniferin, the dimer of Resveratrol and isolated from **Vitis vinifera**, displays a potent inhibitory for all the **CYP** activities, with K_i values from 0.5-20 μM. ε-Viniferin possesses potent antioxidant capacity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg